Vladimir Y Khryshchanovich1, Yuri S Nebylitsin2, Vladimir A Kosinets2. 1. Belarusian State Medical University, Dzerzhinski Ave., 83, Minsk, 220116, Republic of Belarus. vladimirkh77@mail.ru. 2. Vitebsk State Order of Peoples Friendship Medical University, Vitebsk, Republic of Belarus.
Abstract
BACKGROUND: Endovenous interventions and minimally invasive open procedures are effective in the management of varicose veins, but can result in post-operative pain/discomfort. OBJECTIVE: The objective of this study was to evaluate the clinical efficacy of micronized purified flavonoid fraction venoactive therapy for postoperative pain, vein-specific symptoms, and quality of life in patients with varicose veins following an endovenous mechanochemical ablation procedure. METHODS: This prospective, observational, single-center study allocated patients into two groups: Group A, micronized purified flavonoid fraction 1000 mg once daily for 30 days; Group B, no venoactive drug prescribed (control). The Clinical-Etiology-Anatomy-Pathophysiology classification system for chronic venous disorders was used to assess varicose veins; a 10-point Visual Analog Scale assessed pain syndrome intensity; the Venous Clinical Severity Score measured overall varicose vein severity; and the Chronic Venous Insufficiency QoL Questionnaire measured total quality of life. RESULTS: The study enrolled 58 patients (mean age 36.9 ± 4.1 years; 24 men) with varicose veins of C2-C4 who underwent truncal mechanochemical ablation plus mini-phlebectomy or foam sclerotherapy. Group A had significantly lower pain syndrome at days 14 and 30 compared with Group B (1.76 vs 2.20, p = 0.039; 1.38 vs 2.07, p = 0.003, respectively), and clinical symptom severity at day 30 (2.67 vs 3.13, p = 0.05). Significant differences in quality-of-life scores existed between groups at days 14 and 30 (15.21 vs 18.75, p = 0.008; 12.98 vs 16.33, p = 0.001). No micronized, purified flavonoid, fraction-related adverse effects were observed. CONCLUSIONS: Micronized purified flavonoid fraction-based venoactive adjuvant therapy after mechanochemical ablation alleviated pain, reduced the severity of symptoms, and improved the quality of life in patients with varicose veins.
BACKGROUND: Endovenous interventions and minimally invasive open procedures are effective in the management of varicose veins, but can result in post-operative pain/discomfort. OBJECTIVE: The objective of this study was to evaluate the clinical efficacy of micronized purified flavonoid fraction venoactive therapy for postoperative pain, vein-specific symptoms, and quality of life in patients with varicose veins following an endovenous mechanochemical ablation procedure. METHODS: This prospective, observational, single-center study allocated patients into two groups: Group A, micronized purified flavonoid fraction 1000 mg once daily for 30 days; Group B, no venoactive drug prescribed (control). The Clinical-Etiology-Anatomy-Pathophysiology classification system for chronic venous disorders was used to assess varicose veins; a 10-point Visual Analog Scale assessed pain syndrome intensity; the Venous Clinical Severity Score measured overall varicose vein severity; and the Chronic Venous Insufficiency QoL Questionnaire measured total quality of life. RESULTS: The study enrolled 58 patients (mean age 36.9 ± 4.1 years; 24 men) with varicose veins of C2-C4 who underwent truncal mechanochemical ablation plus mini-phlebectomy or foam sclerotherapy. Group A had significantly lower pain syndrome at days 14 and 30 compared with Group B (1.76 vs 2.20, p = 0.039; 1.38 vs 2.07, p = 0.003, respectively), and clinical symptom severity at day 30 (2.67 vs 3.13, p = 0.05). Significant differences in quality-of-life scores existed between groups at days 14 and 30 (15.21 vs 18.75, p = 0.008; 12.98 vs 16.33, p = 0.001). No micronized, purified flavonoid, fraction-related adverse effects were observed. CONCLUSIONS: Micronized purified flavonoid fraction-based venoactive adjuvant therapy after mechanochemical ablation alleviated pain, reduced the severity of symptoms, and improved the quality of life in patients with varicose veins.
Authors: C Wittens; A H Davies; N Bækgaard; R Broholm; A Cavezzi; S Chastanet; M de Wolf; C Eggen; A Giannoukas; M Gohel; S Kakkos; J Lawson; T Noppeney; S Onida; P Pittaluga; S Thomis; I Toonder; M Vuylsteke; P Kolh; G J de Borst; N Chakfé; S Debus; R Hinchliffe; I Koncar; J Lindholt; M V de Ceniga; F Vermassen; F Verzini; M G De Maeseneer; L Blomgren; O Hartung; E Kalodiki; E Korten; M Lugli; R Naylor; P Nicolini; A Rosales Journal: Eur J Vasc Endovasc Surg Date: 2015-04-25 Impact factor: 7.069
Authors: Andrew Nicolaides; Stavros Kakkos; Niels Baekgaard; Anthony Comerota; Marianne de Maeseneer; Bo Eklof; Athanasios D Giannoukas; Marzia Lugli; Oscar Maleti; Ken Myers; Olle Nelzén; Hugo Partsch; Michel Perrin Journal: Int Angiol Date: 2018-06 Impact factor: 2.789
Authors: Suzanne Holewijn; Ramon R J P van Eekeren; Anco Vahl; Jean Paul P M de Vries; Michel M P J Reijnen Journal: J Vasc Surg Venous Lymphat Disord Date: 2019-05
Authors: Ahmed Hassanin; Thomas M Aherne; Garrett Greene; Emily Boyle; Bridget Egan; Sean Tierney; Stewart R Walsh; Seamus McHugh; Sayed Aly Journal: J Vasc Surg Venous Lymphat Disord Date: 2019-11
Authors: Vicente Mosquera-Rey; José A Del Castro Madrazo; María Ángeles M Herrero; Rubén A Cordeu; Ernesto A Azofra; Manuel A Pérez Journal: Phlebology Date: 2020-08-26 Impact factor: 1.740